PMS-GENTAMICIN-BETAMETHASONE DIN 02238819
Status: Cancelled Pre Market
Holder: PHARMASCIENCE INC
Health Canada record
| Active ingredient(s) | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 1 MG; GENTAMICIN (GENTAMICIN SULFATE) 3 MG |
|---|---|
| Dosage form | Liquid |
| Route | Otic; Ophthalmic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S03CA06 BETAMETHASONE AND ANTIINFECTIVES |
| Original market date | |
| Current status date | 01-Mar-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pharmascience Inc. — licence 100241, currently licensed, last inspection rating C (2025-03-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02060884 | BETNESOL RETENTION ENEMA 5MG/100ML | PALADIN PHARMA INC. | Enema | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 5 MG | Cancelled Post Market |
| 02063190 | BETNESOL TABLETS | SHIRE PHARMA CANADA ULC | Tablet (Effervescent) | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 0.5 MG | Cancelled Post Market |
| 00176834 | CELESTONE REPETABS 1MG | SCHERING-PLOUGH CANADA INC | Tablet (Extended-Release) | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 1 MG | Cancelled Post Market |
| 02238818 | DOM-GENTAMICIN-BETAMETHASONE | DOMINION PHARMACAL | Liquid | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 1 MG; GENTAMICIN (GENTAMICIN SULFATE) 3 MG | Cancelled Pre Market |
| 00682217 | GARASONE OPHTHALMIC AND OTIC SOLUTION | MERCK CANADA INC | Solution | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 1 MG; GENTAMICIN (GENTAMICIN SULFATE) 3 MG | Cancelled Post Market |
| 00586706 | GARASONE OPHTHALMIC OINTMENT | MERCK CANADA INC | Ointment | BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 1 MG; GENTAMICIN (GENTAMICIN SULFATE) 3 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 2713 | 1998-10-06 | New Drug Submission (NDS) |